Lectures were provided by WDOM faculty and keynote speaker, Dr. Drew Weissman, who played a major role in critical discoveries that allowed for the mRNA platform to be used in developing vaccines against SARS-CoV.
The HOPE (HIV Obstruction by Programmed Epigenetics) Collaboratory represents a completely new strategy for curing HIV. Utilizing previous knowledge regarding how other viruses have become naturally inactivated over time, the HOPE approach aims to silence and permanently remove HIV from the body.
As part of The Martin Delaney Collaboratories, which is an NIH flagship funding mechanism, Dr. Jones will be leading REACH (Research Enterprise to Advance a Cure for HIV) in pursuit of a cure for HIV.
The research from Drs. Ndhlovu and Corley finds that abrupt and altered cell-type specific DNA methylation profiles in blood, seen during acute HIV infection, persist despite prompt initiation of antiretroviral therapy.
This award is presented annually to members of the Weill Department of Medicine below the rank of professor who perform on outstanding levels in the areas of clinical and/or basic biomedical research.
Drs. Timothy Powell, Douglas Nixon, and Rodrigo Duarte have published a paper in Clinical & Translational Immunology that has identified three key inflammatory proteins that may be involved in the risk of acquiring severe COVID-19.
The Fund for the Future award supports selected junior faculty during the crucial period of career development spanning completion of research training through the early years of their first faculty position at WCM.
A clinician and dedicated researcher in healthcare epidemiology, infection prevention, and antibiotic stewardship, Dr. Calfee has served as an associate editor of the journal over the past several years.
Dr. Roy M. Gulick and colleagues have received a renewal from the NIAID in support of their HIV CTU grant in the amount of $18.9 million through 2027. The renewal provides funding for the AIDS Clinical Trials Group and HIV Prevention Trials Network.
Dr. Brad Jones, Division of Infectious Diseases, began a collaboration several years ago involving T-cell therapy approaches to HIV that has played a key role in a breakthrough study on COVID-19.